Differential biochemical and cellular actions of premarin estrogens: Distinct pharmacology of bazedoxifene-conjugated estrogens combination

Molecular Endocrinology

Volumn 23, Issue 1, 2009, Pages 74-85

  Berrodin, Thomas J ^a   Chang, Ken C N ^a   Komm, Barry S ^a   Freedman, Leonard P ^a   Nagpal, Sunil ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA DIHYDROEQUILENIN; 17ALPHA ESTRADIOL; 17BETA DIHYDROEQUILENIN; 17BETA DIHYDROEQUILIN; BAZEDOXIFENE; CELL NUCLEUS RECEPTOR; CONJUGATED ESTROGEN; DELTA 8,9 DEHYDROSTERONE; EQUILENIN; EQUILIN; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTRONE; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMISTRY; CELL ACTIVITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BINDING SITES; BONE DENSITY CONSERVATION AGENTS; CELL LINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS, CONJUGATED (USP); FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDOLES; LIGANDS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRANSCRIPTIONAL ACTIVATION;

EID: 58149218461     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2008-0366     Document Type: Article

References (33)

1. Nelson HD 2008 Menopause. Lancet 371:760-770
2. Cooper C, O'Neill T, Silman A 1993 The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone 14(Suppl 1):S89-S97
3. Melton LI 1997 Epidemiology of spinal osteoporosis. Spine 22:2S-11S
4. Melton LJ, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL 1989 Epidemiology of vertebral fractures in women. Am J Epidemiol 129:1000-1011
5. Wasnich RD 1996 Vertebral fracture epidemiology. Bone 18(Suppl 3):179S-S183
6. Walf AA, Frye CA 2008 Conjugated equine estrogen enhances rats' cognitive, anxiety, and social behavior. Neuroreport 19:789-792
7. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, et al., Women's Health Initiative Steering Committee 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
8. Writing group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postsmenopausal women. JAMA 288:321-333
9. Lewiecki EM 2007 Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 16:1663-1672
10. Hansdóttir H 2008 Raloxifene for older women: a review of the literature. Clin Interv Aging 3:45-50
11. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
12. Gennari L, Merlotti D, Martini G, Nuti R 2006 Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opin Investig Drugs 15:1091-1103
13. Kharode Y, Bodine P, Miller CP, Lyttle CR, Komm BS 2008 The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149:6084-6091
14. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
15. Ma L, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR, Bramlett KS, Zeng QQ, Chandrasekhar S, Yu XP, Linebarger JH, Iturria SJ, Burris TP, Kato S, Chin WW, Nagpal S 2006 Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 116:892-904
16. Chang C, McDonnell D 2005 Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 26:225-228
17. Savkur RS, Bramlett KS, Clawson D, Burris TP 2004 Pharmacology of nuclear receptor-coregulator recognition. Vitam Horm 68:145-183
18. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736
19. Folkertsma S, van Noort PI, de Heer A, Carati P, Brandt R, Visser A, Vriend G, de Vlieg J 2007 The use of in vitro peptide binding profiles and in silico ligand-receptor interaction profiles to describe ligand-induced conformations of the retinoid X receptor α ligand-binding domain. Mol Endocrinol 21:30-48
20. Iannone MA, Simmons CA, Kadwell SH, Svoboda DL, Vanderwall DE, Deng SJ, Consler TG, Shearin J, Gray JG, Pearce KH 2004 Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol Endocrinol 18:1064-1081
21. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, Nakamura M, Miao S, Cao P, Learned RM, Chen JL, Li Y 2002 T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities. J Biol Chem 277:19649-19657
22. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP 1999 Peptide antagonists of the human estrogen receptor. Science 285:744-746
23. Paige LA, Christensen DJ, Grøn H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β. Proc Natl Acad Sci USA 96:3999-4004
24. Bhavnani BR 2003 Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol 85:473-482
25. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettingerm M, Stefanick ML, Wactawski-Wende J, Watts NB Women's Health Initiative Investigators 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290:1729-1738
26. Lukes A 2008 Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative. J Manag Care Pharm 14(Suppl 3):7-13
27. Lonard DM, Lanz RB, O'Malley BW 2007 Nuclear receptor coregulators and human disease. Endocr Rev 28:575-587
28. Okada M, Takezawa S, Mezaki Y, Yamaoka I, Takada I, Kitagawa H, Kato S 2008 Switching of chromatin-remodelling complexes for oestrogen receptor-α. EMBO Rep 9:563-568
29. Rachez C, Gamble M, Chang C-PB, Atkins GB, Lazar MA, Freedman LP 2000 The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Mol Cell Biol 20:2718-2726
30. Dai SY, Chalmers MJ, Bruning J, Bramlett KS, Osborne HE, Montrose-Rafizadeh C, Barr RJ, Wang Y, Wang M, Burris TP, Dodge JA, Griffin PR 2008 Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method. Proc Natl Acad Sci USA 105:7171-7176
31. Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M2008 Unique ERα cistromes control cell type-specific gene regulation. Mol Endocrinol 22:2393-2406
32. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M 2006 Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289-1297
33. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M 2008 FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132:958-970